Anemia represents an almost obligatory complication in patients with chronic kidney disease (CKD) and, if ineffectively treated, is associated with increased cardiovascular (CV) mortality, a reduced quality of life and the well know clinical consequences secondary to the need of an exceedingly high number of iron infusions and red blood cell (RBC) transfusions, which have been the only available therapy until the end of 1980s [1,2].
